1. Home
  2. RGLS
  3. RGLS News

Latest Regulus Therapeutics Inc. (RGLS) News on October 18, 2024

RGLS

MT Newswires

9 days ago

Regulus Therapeutics Completes Enrollment in Phase 1b Kidney Disease Drug Trial

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RGLS

PR Newswire

10 days ago

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
RGLS

PR Newswire

2 months ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
RGLS

Simply Wall St.

2 months ago

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

RGLS

Associated Press Finance

2 months ago

Regulus: Q2 Earnings Snapshot

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
RGLS

PR Newswire

2 months ago

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
RGLS

PR Newswire

2 months ago

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

RGLS

MT Newswires

3 months ago

Oppenheimer Initiates Regulus Therapeutics at Outperform With $7 Price Target

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
RGLS

PR Newswire

3 months ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

RGLS

MT Newswires

4 months ago

Canaccord Genuity Raises Price Target on Regulus Therapeutics to $28 From $11, Maintains Buy Rating

RGLS

MT Newswires

4 months ago

HC Wainwright Raises Regulus Therapeutics Price Target to $10 From $9, Maintains Buy Rating

RGLS

MT Newswires

4 months ago

Regulus Therapeutics Says Potential Kidney Disease Drug Well-Tolerated in Phase 1b Study

RGLS

MT Newswires

4 months ago

Top Premarket Gainers

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RGLS

PR Newswire

4 months ago

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
RGLS

Simply Wall St.

4 months ago

Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes
RGLS

PR Newswire

4 months ago

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
RGLS

PR Newswire

5 months ago

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

RGLS

Associated Press Finance

5 months ago

Regulus: Q1 Earnings Snapshot

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
RGLS

PR Newswire

5 months ago

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RGLS

PR Newswire

5 months ago

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
RGLS

PR Newswire

6 months ago

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

RGLS

GuruFocus.com

7 months ago

Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements

RGLS

Associated Press Finance

7 months ago

Regulus: Q4 Earnings Snapshot

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
RGLS

PR Newswire

7 months ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
RGLS

Zacks

7 months ago

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS

Zacks

7 months ago

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
RGLS

PR Newswire

7 months ago

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RGLS

PR Newswire

7 months ago

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
RGLS

GlobeNewswire

9 months ago

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Vuzix Expands Its Market Leadership in Optical Waveguides with the Addition of Integrated Vision Correction Prescriptions
RGLS

PR Newswire

9 months ago

Vuzix Expands Its Market Leadership in Optical Waveguides with the Addition of Integrated Vision Correction Prescriptions

CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS
RGLS

PR Newswire

9 months ago

CFSB BANCORP, INC. ANNOUNCES FISCAL SECOND QUARTER AND YEAR-TO-DATE 2024 FINANCIAL RESULTS

Q3 Earnings Roundup: Amtech (NASDAQ:ASYS) And The Rest Of The Semiconductor Manufacturing Segment
RGLS

StockStory

9 months ago

Q3 Earnings Roundup: Amtech (NASDAQ:ASYS) And The Rest Of The Semiconductor Manufacturing Segment

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
RGLS

GlobeNewswire

9 months ago

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

Invesco Municipal Trust's Dividend Analysis
RGLS

GuruFocus.com

9 months ago

Invesco Municipal Trust's Dividend Analysis

RGLS

Market Exclusive

9 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Urban Farming Frontiers: 3 Stocks Growing Greens in the City
RGLS

InvestorPlace

9 months ago

Urban Farming Frontiers: 3 Stocks Growing Greens in the City

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024
RGLS

CNW Group

9 months ago

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RGLS

PR Newswire

9 months ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Pioneer Power Announces e-Bloc and Related Product Orders in Excess of $10 Million
RGLS

Business Wire

10 months ago

Pioneer Power Announces e-Bloc and Related Product Orders in Excess of $10 Million

Intuitive Machines Announces Strategic Partnership and Leadership Changes
RGLS

GlobeNewswire

10 months ago

Intuitive Machines Announces Strategic Partnership and Leadership Changes

FingerMotion's Big Data Update
RGLS

ACCESSWIRE

10 months ago

FingerMotion's Big Data Update

Pioneer Power Announces e-Boost Orders Totaling $3.1 Million
RGLS

Business Wire

10 months ago

Pioneer Power Announces e-Boost Orders Totaling $3.1 Million

Hywin's debacle underscores close links between China's property and wealth management sectors
RGLS

South China Morning Post

10 months ago

Hywin's debacle underscores close links between China's property and wealth management sectors

We Like These Underlying Return On Capital Trends At L.S. Starrett (NYSE:SCX)
RGLS

Simply Wall St.

10 months ago

We Like These Underlying Return On Capital Trends At L.S. Starrett (NYSE:SCX)

RGLS

PR Newswire

10 months ago

Scienjoy Holding Corporation Reports Nine months ended September 30, 2023 Unaudited Financial Results

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
RGLS

PR Newswire

10 months ago

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Pioneer Closed End Funds Required Notice to Shareholders Sources of Distribution Under Section 19(a)
RGLS

Business Wire

a year ago

Pioneer Closed End Funds Required Notice to Shareholders Sources of Distribution Under Section 19(a)

inTEST Corporation Announces Stock Repurchase Plan
RGLS

Business Wire

a year ago

inTEST Corporation Announces Stock Repurchase Plan

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
RGLS

PR Newswire

a year ago

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

RGLS

Associated Press Finance

a year ago

Regulus: Q3 Earnings Snapshot

Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
RGLS

GlobeNewswire

a year ago

Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
RGLS

PR Newswire

a year ago

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

The past three years for KORU Medical Systems (NASDAQ:KRMD) investors has not been profitable
RGLS

Simply Wall St.

a year ago

The past three years for KORU Medical Systems (NASDAQ:KRMD) investors has not been profitable

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
RGLS

GlobeNewswire

a year ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Katapult Delivers 10% Year-Over-Year Revenue Growth In Third Quarter 2023
RGLS

GlobeNewswire

a year ago

Katapult Delivers 10% Year-Over-Year Revenue Growth In Third Quarter 2023

Share on Social Networks: